Brittany M Charlton1,2, Sari L Reisner2,3,4,5, Madina Agénor6,7, Allegra R Gordon1,2, Vishnudas Sarda1, S Bryn Austin1,2,7,8. 1. 1 Division of Adolescent/Young Adult Medicine, Boston Children's Hospital , Boston, Massachusetts. 2. 2 Department of Pediatrics, Harvard Medical School , Boston, Massachusetts. 3. 3 Division of General Pediatrics, Boston Children's Hospital , Boston, Massachusetts. 4. 4 The Fenway Institute , Fenway Health, Boston, Massachusetts. 5. 5 Department of Epidemiology, Harvard T.H. Chan School of Public Health , Boston, Massachusetts. 6. 6 Dana-Farber Cancer Institute , Boston, Massachusetts. 7. 7 Department of Social and Behavioral Sciences, Harvard T.H. Chan School of Public Health , Boston, Massachusetts. 8. 8 Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital , Boston, Massachusetts.
Abstract
PURPOSE: This study sought to examine how human papillomavirus (HPV) vaccination may differ across sexual orientation groups (e.g., bisexuals compared to heterosexuals)-particularly in boys and men, about whom little is known. METHODS: Data were from a prospective cohort of 10,663 U.S. females and males enrolled in the Growing Up Today Study followed from 1996 to 2014. Participants were aged 11-24 years when the vaccine was approved for females in 2006 and 14-27 years when approved for males in 2009. In addition to reporting sexual orientation identity/attractions, participants reported sex of lifetime sexual partners. Log-binominal models were used to examine HPV vaccination across sexual orientation groups. RESULTS: Among females, 56% received ≥1 dose. In contrast, 8% of males obtained ≥1 dose; HPV vaccination initiation was especially low among completely heterosexual males. After adjusting for potential confounders, completely heterosexual (risk ratio [RR]; 95% confidence interval [CI]: 0.45 [0.30-0.68]) and mostly heterosexual (RR; 95% CI: 0.44 [0.25-0.78]) males were half as likely to have received even a single dose compared to gay males. Compared to lesbians, no differences were observed for completely heterosexual or bisexual females, but mostly heterosexual females were 20% more likely to have received at least one dose. CONCLUSIONS: HPV vaccination rates in the U.S. are strikingly low and special attention is needed for boys and men, especially those who do not identify as gay. Vaccinating everyone, regardless of sex/gender and/or sexual orientation, will not only lower that individual's susceptibility but also decrease transmission to partners, females and/or males, to help eradicate HPV through herd immunity.
PURPOSE: This study sought to examine how human papillomavirus (HPV) vaccination may differ across sexual orientation groups (e.g., bisexuals compared to heterosexuals)-particularly in boys and men, about whom little is known. METHODS: Data were from a prospective cohort of 10,663 U.S. females and males enrolled in the Growing Up Today Study followed from 1996 to 2014. Participants were aged 11-24 years when the vaccine was approved for females in 2006 and 14-27 years when approved for males in 2009. In addition to reporting sexual orientation identity/attractions, participants reported sex of lifetime sexual partners. Log-binominal models were used to examine HPV vaccination across sexual orientation groups. RESULTS: Among females, 56% received ≥1 dose. In contrast, 8% of males obtained ≥1 dose; HPV vaccination initiation was especially low among completely heterosexual males. After adjusting for potential confounders, completely heterosexual (risk ratio [RR]; 95% confidence interval [CI]: 0.45 [0.30-0.68]) and mostly heterosexual (RR; 95% CI: 0.44 [0.25-0.78]) males were half as likely to have received even a single dose compared to gay males. Compared to lesbians, no differences were observed for completely heterosexual or bisexual females, but mostly heterosexual females were 20% more likely to have received at least one dose. CONCLUSIONS:HPV vaccination rates in the U.S. are strikingly low and special attention is needed for boys and men, especially those who do not identify as gay. Vaccinating everyone, regardless of sex/gender and/or sexual orientation, will not only lower that individual's susceptibility but also decrease transmission to partners, females and/or males, to help eradicate HPV through herd immunity.
Authors: Elizabeth M Saewyc; Greta R Bauer; Carol L Skay; Linda H Bearinger; Michael D Resnick; Elizabeth Reis; Aileen Murphy Journal: J Adolesc Health Date: 2004-10 Impact factor: 5.012
Authors: A E Field; C A Camargo; C B Taylor; C S Berkey; A L Frazier; M W Gillman; G A Colditz Journal: J Am Acad Child Adolesc Psychiatry Date: 1999-06 Impact factor: 8.829
Authors: S D Cochran; V M Mays; D Bowen; S Gage; D Bybee; S J Roberts; R S Goldstein; A Robison; E J Rankow; J White Journal: Am J Public Health Date: 2001-04 Impact factor: 9.308
Authors: Caitlin Loretan; Allison T Chamberlain; Travis Sanchez; Maria Zlotorzynska; Jeb Jones Journal: Sex Transm Dis Date: 2019-07 Impact factor: 2.830
Authors: Kaan Z Apaydin; Holly B Fontenot; Derri Shtasel; Sannisha K Dale; Christina P C Borba; Christopher S Lathan; Lori Panther; Kenneth H Mayer; Alex S Keuroghlian Journal: Vaccine Date: 2018-05-16 Impact factor: 3.641